MA40498A - Méthode de traitement de l'intoxication par organophosphates - Google Patents
Méthode de traitement de l'intoxication par organophosphatesInfo
- Publication number
- MA40498A MA40498A MA040498A MA40498A MA40498A MA 40498 A MA40498 A MA 40498A MA 040498 A MA040498 A MA 040498A MA 40498 A MA40498 A MA 40498A MA 40498 A MA40498 A MA 40498A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- organophosphate poisoning
- organophosphate
- poisoning
- Prior art date
Links
- 208000007964 Organophosphate Poisoning Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462044635P | 2014-09-02 | 2014-09-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA40498A true MA40498A (fr) | 2021-05-19 |
Family
ID=55440310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA040498A MA40498A (fr) | 2014-09-02 | 2015-09-01 | Méthode de traitement de l'intoxication par organophosphates |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10172870B2 (fr) |
| EP (1) | EP3188734A4 (fr) |
| MA (1) | MA40498A (fr) |
| WO (1) | WO2016036724A1 (fr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014028398A2 (fr) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation de crises épileptiques par une polythérapie à l'aide de benzodiazépines et de neurostéroïdes |
| CN117304245A (zh) | 2013-04-17 | 2023-12-29 | 萨奇治疗股份有限公司 | 刺激神经活性的19-去甲类固醇及其使用方法 |
| SMT202100509T1 (it) | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| WO2014169836A1 (fr) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor-stéroïdes neuroactifs et procédés d'utilisation de ceux-ci |
| CA2918735C (fr) | 2013-07-19 | 2023-08-01 | Sage Therapeutics, Inc. | Steroides neuroactifs, compositions, et leurs utilisations |
| CN105579043B (zh) | 2013-08-23 | 2021-09-14 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物和其用途 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| MY190408A (en) | 2014-10-16 | 2022-04-21 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| US20170233433A1 (en) | 2014-10-16 | 2017-08-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| WO2016082789A1 (fr) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions et procédés pour traiter des troubles du snc |
| LT3250210T (lt) | 2015-01-26 | 2021-04-12 | Sage Therapeutics, Inc. | Kompozicijos ir būdai, skirti gydyti cns sutrikimus |
| DK3258939T3 (da) | 2015-02-20 | 2022-12-12 | Sage Therapeutics Inc | Neuroaktive steroider, sammensætninger og anvendelser heraf |
| MA43284A (fr) * | 2015-11-20 | 2018-09-26 | Sage Therapeutics Inc | Composés et leurs méthodes d'utilisation |
| CA3030420C (fr) | 2016-07-11 | 2025-11-18 | Sage Therapeutics, Inc. | Steroides neuroactifs substitues en c7, c12 et c16 et methodes d'utilisation associees |
| WO2018013613A1 (fr) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| WO2019226515A1 (fr) * | 2018-05-21 | 2019-11-28 | The University Of North Carolina At Chapel Hill | Procédés d'inhibition de signalisation neuro-immunitaire pro-inflammatoire et méthodes de traitement de troubles inflammatoires |
| CZ309617B6 (cs) | 2019-04-05 | 2023-05-24 | Ústav organické chemie a biochemie AV ČR, v. v. i | 3α5ß-Neuroaktivní steroidy pro léčbu epilepsie a záchvatových onemocnění |
| WO2020231837A1 (fr) | 2019-05-10 | 2020-11-19 | Brii Biosciences, Inc. | Composition pharmaceutique à base de brexanolone, de ganaxolone ou de zuranolone, et son utilisation |
| JP7670626B2 (ja) | 2019-05-31 | 2025-04-30 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド及びその組成物 |
| EP4009982A4 (fr) | 2019-08-05 | 2023-08-09 | Marinus Pharmaceuticals, Inc. | Ganaxolone destinée à être utilisée dans le traitement de l'état de mal épileptique |
| CN115551514A (zh) * | 2020-03-25 | 2022-12-30 | 萨奇治疗股份有限公司 | 用于治疗呼吸系统病症的药物的用途 |
| US12005185B2 (en) | 2021-12-17 | 2024-06-11 | Belhaven BioPharma Inc. | Medical counter measures including dry powder formulations and associated methods |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5319115A (en) | 1987-08-25 | 1994-06-07 | Cocensys Inc. | Method for making 3α-hydroxy, 3β-substituted-pregnanes |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5521215A (en) | 1989-11-07 | 1996-05-28 | Ramot University Authority For Applied Research And Industrial Development Ltd. | NMDA-blocking pharmaceuticals |
| AU6044994A (en) | 1993-02-19 | 1994-09-14 | Nippon Shinyaku Co. Ltd. | Glycerol derivative, device and pharmaceutical composition |
| JP4008024B2 (ja) | 1993-05-24 | 2007-11-14 | パーデュー、ファーマ、リミテッド、パートナーシップ | Ｇａｂａａレセプター複合体と相互作用させるための化合物 |
| DK1038880T3 (da) | 1994-02-14 | 2008-03-03 | Euro Celtique Sa | Androstaner og pregnaner til allosterisk modulering af GABA-receptor |
| BR9509764A (pt) | 1994-11-23 | 1998-07-07 | Cocensys Inc | Série androstano e pregnano para modulação alostérica de receptor de gaba |
| PT837874E (pt) | 1995-06-06 | 2005-03-31 | Euro Celtique Sa | Esteroides neuroactivos da serie androstano e pregnano |
| US5994316A (en) | 1996-02-21 | 1999-11-30 | The Immune Response Corporation | Method of preparing polynucleotide-carrier complexes for delivery to cells |
| CA2527019A1 (fr) | 2003-05-29 | 2005-01-06 | Washington University | 13,24-cyclo-18,21-dinorcholanes neuroactifs et steroides pentacycliques structurellement associes |
| CA2698172C (fr) | 2007-06-15 | 2014-02-18 | Cook, Kevin M. | Steroides d'androstane et de pregnane presentant de puissantes proprietes de modulation allosterique du complexe recepteur gaba/ionophore chlorure |
| US20090156650A1 (en) * | 2007-09-19 | 2009-06-18 | Serb | Composition that comprises at least one oxime and its use in therapeutics |
| US20130309306A1 (en) | 2010-12-01 | 2013-11-21 | The Regents Of The University Of California | Intrapulmonary benzodiazepine for the treatment and prevention of seizures |
| WO2013019711A2 (fr) | 2011-07-29 | 2013-02-07 | The Regents Of The University Of California | Nouveaux stéroïdes substitués en 17β par un hétéroaryle, capables de moduler les récepteurs gabaa |
| US10478505B2 (en) | 2011-09-23 | 2019-11-19 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| WO2014028398A2 (fr) * | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation de crises épileptiques par une polythérapie à l'aide de benzodiazépines et de neurostéroïdes |
| RS62761B1 (sr) | 2012-08-21 | 2022-01-31 | Sage Therapeutics Inc | Alopregnanolon za lečenje refraktornog epileptičkog statusa |
| US20150313868A1 (en) | 2012-12-18 | 2015-11-05 | Kotzker Consulting Llc | Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity |
-
2015
- 2015-09-01 MA MA040498A patent/MA40498A/fr unknown
- 2015-09-01 WO PCT/US2015/047914 patent/WO2016036724A1/fr not_active Ceased
- 2015-09-01 US US15/508,233 patent/US10172870B2/en active Active
- 2015-09-01 EP EP15838694.6A patent/EP3188734A4/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20170246188A1 (en) | 2017-08-31 |
| EP3188734A1 (fr) | 2017-07-12 |
| WO2016036724A1 (fr) | 2016-03-10 |
| US10172870B2 (en) | 2019-01-08 |
| EP3188734A4 (fr) | 2018-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3380121A4 (fr) | Méthode de traitement de troubles oculaires | |
| EP3188734A4 (fr) | Méthode de traitement de l'intoxication par organophosphates | |
| MA52371A (fr) | Méthodes de traitement d'infections dues aux coronaviridae | |
| EP3500289A4 (fr) | Procédés de traitement de la trachéobronchomalacie | |
| EP3448504A4 (fr) | Traitement de stimulation cérébrale pour dépression | |
| EP3500264A4 (fr) | Méthode de traitement de l'oesophagite éosinophile | |
| LT3556775T (lt) | Anti-lag-3 antikūnai, skirti hematologinių piktybinių susirgimų gydymui | |
| EP3522934A4 (fr) | Compositions et méthode pour le traitement de la rénopathie | |
| EP3341080A4 (fr) | Méthode de traitement du cancer | |
| LT3204398T (lt) | Gemcitabino fosfato diastereoizomerų atskyrimo būdai | |
| EP3455188C0 (fr) | Procede de traitement de laitier | |
| EP3286171A4 (fr) | Procédés de stimulation hydraulique des cultures | |
| EP3375440A4 (fr) | Méthode de traitement de la mucosite | |
| EP3422943A4 (fr) | Méthode de traitement d'intoxication médicamenteuse | |
| IL256103B (en) | Compositions and methods for treating celiac sprue disease | |
| PT3233071T (pt) | Método de tratamento ou prevenção de doenças mediadas por ras | |
| FR3039368B1 (fr) | Procede de traitement cosmetique | |
| EP3448365A4 (fr) | Méthode de traitement de la constipation | |
| EP3436080A4 (fr) | Méthode de préparation de sperme | |
| IL257764B (en) | Methods for treatment of diseases | |
| MA41462A (fr) | Méthode de traitement de maladies | |
| FR3034011B1 (fr) | Procede de traitement cosmetique des cheveux | |
| MA41636A (fr) | Méthode de traitement de la cholangite sclérosante primitive | |
| EP3316887A4 (fr) | Inhibiteurs de gls1 pour le traitement de maladies | |
| EP3440107A4 (fr) | Méthode de traitement de l'athérosclérose |